It’s never too early — or too late — to make changes that may prevent, delay, or slow the progression of dementia. Research suggests that these changes could carry as much clout as our genes. UCSF expert Kristine Yaffe, MD, explores how targeting modifiable risk factors—like sleep and exercise—can…
This new approach to improve walking for people with Parkinson’s Disease could open a new chapter in personalized neuromodulation. UC San Francisco researchers have developed a new form of deep brain stimulation (DBS) that adjusts in real time as a person walks, helping to improve gait and reduce…
A gifted clinician, educator, and research leader, Josephson will helm the school in a time of rapid change. S. Andrew Josephson, MD, a master clinician and educator who has led UCSF’s top-ranked Department of Neurology since 2017, has been named the next dean of the UCSF School of Medicine and…
Once blood vessels lose the ability to expand and contract with each heartbeat, artery walls are more prone to rupture. Ethan Winkler, who studies aneurysms, discovered a dynamic between cells in the brain's blood vessels that explains why aneurysms burst. The findings describe a "life…
More than 20 years ago, virtually nothing was known about pediatric stroke. Today, UCSF research fuels life-saving advances in care. Two decades ago, children with stroke were falling into this gap between stroke providers who didn’t treat children and child neurologists who were uncomfortable…
Biomarkers in midlife adults without dementia may be linked to the earliest signs of waning cognition, researchers found. About 6% of asymptomatic adults have a biomarker for Alzheimer's disease and are already showing very subtle signs of the disease that would not come to light in a…
A team at UCSF developed a multitask deep learning framework that can effectively predict Alzheimer’s disease diagnosis, cognitive scores, and future cognitive decline using only baseline MRI and demographics.
UCSF and Trinity College Dublin researchers determine cost-effective thresholds for Alzheimer’s-modifying therapies in 174 countries. In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These…
UCSF experts share their research on medications’ potential to slow or reduce risk of dementia and to treat the triggers that drive addiction. Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular conditions. New evidence…
Scientists at UCSF discovered that these tiny bursts of electrical activity can be detected up to a second before they start. Epilepsy physicians Jon Kleen and Eddie Chang used high-resolution technology to see how cognition is disrupted in people with epilepsy and predict when it will occur. The…
